Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695036 | 0.86 | OPRL1 (0.57) | OPRL1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL15566855 | 0.85 | KDM1A (0.55) | OPRL1KDM1AKDM1BPTGDR2 | |
| SCHEMBL20103351 | 0.85 | ESR2 (0.54) | OPRL1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL20103372 | 0.81 | ESR1 (0.39) | OPRL1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL21644870 | 0.81 | ESR1 (0.39) | OPRL1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL29487576 | 0.80 | KDM1A (0.47) | OPRL1ESR2KDM1AKDM1BPSEN1 | |
| SCHEMBL22321256 | 0.80 | KDM1A (0.47) | OPRL1ESR2KDM1AKDM1BPSEN1 | |
| SCHEMBL28705118 | 0.80 | ESR1 (0.43) | OPRL1ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL22321255 | 0.80 | KDM1A (0.47) | OPRL1ESR2KDM1AKDM1BPSEN1 | |
| SCHEMBL20103540 | 0.80 | FFAR1 (0.51) | ESR1ESR2CYP3A4CYP2C9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | OPRL1 103/4885ESR1 243/4885ESR2 97/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | OPRL1 103/4885ESR1 243/4885ESR2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.